Why did Thomas Malley resign from the Board?

According to the filing, Mr. Malley's resignation was not the result of any disagreement with respect to the operations, policies, or practices of the Company.

What is Olivier Brandicourt's background and why is it relevant to BeiGene?

Dr. Brandicourt has extensive experience in the global pharmaceutical industry, including senior leadership roles such as CEO of Sanofi and Bayer HealthCare, and is a Senior Advisor at Blackstone Life Sciences. His deep operational, commercial, and management expertise in healthcare is expected to provide valuable strategic guidance to BeiGene.

What compensation will Dr. Brandicourt receive?

Dr. Brandicourt will receive compensation consistent with BeiGene's independent director policy. This includes a pro-rated grant of share options valued at $400,000, pro-rated annual cash compensation of $65,000 for his director role, and $17,500 for his Audit Committee service, along with reimbursement for expenses. He will also be entitled to future compensation and equity grants.

Are there any related party transactions or special arrangements with Dr. Brandicourt?

The filing states there are no arrangements or understandings with other persons regarding his election, nor are there any transactions between Dr. Brandicourt and the Company that would require disclosure under Item 404(a) of Regulation S-K.

ONC/BEIGF 8-K: Leadership Changes

Summary

BeiGene, Ltd. (ONC) announced a change to its Board of Directors via an 8-K filing on January 23, 2024. Thomas Malley resigned from the Board, including his committee memberships, effective January 22, 2024. This departure was stated as not being due to any disagreement with the company's operations, policies, or practices. To fill the vacancy, the Board appointed Olivier Brandicourt, M.D. as a Class II director. Dr. Brandicourt brings extensive global pharmaceutical experience, having previously held senior leadership roles at Sanofi, Bayer, and Pfizer, and is currently a Senior Advisor at Blackstone Life Sciences. His appointment is expected to strengthen the Board's expertise, particularly within the life sciences and healthcare sectors. Dr. Brandicourt's appointment is effective immediately and he will serve until the 2024 Annual General Meeting of Shareholders. He has also been appointed to the Audit Committee. His compensation will align with the company's existing independent director policies, including a pro-rated grant of share options valued at $400,000 and annual cash compensation of $65,000 as a director, plus $17,500 for his Audit Committee role, also pro-rated. Investors should note that Dr. Brandicourt's prior experience includes significant executive positions at major pharmaceutical companies and current board roles in the biotech industry, suggesting a strategic focus on leveraging deep industry knowledge for the company's growth.

Key Highlights

1Thomas Malley resigned from BeiGene's Board of Directors, including the Audit and Scientific Advisory Committees.
2Mr. Malley's resignation was not due to any disagreement with the Company.
3Olivier Brandicourt, M.D. has been appointed to fill the Board vacancy as a Class II director.
4Dr. Brandicourt brings over 30 years of global pharmaceutical industry experience, including CEO roles at Sanofi and Bayer HealthCare.
5He is currently a Senior Advisor at Blackstone Life Sciences and serves on multiple other biotech boards.
6Dr. Brandicourt has been appointed to the Audit Committee of the Board.
7His compensation includes pro-rated share options valued at $400,000 and annual cash compensation for director and committee service.

BeOne Medicines Ltd. 8-K Report, Executive Changes (Jan 23, 2024)

Summary

Key Highlights

Frequently Asked Questions